Skip to main content
Clinical Trials/NCT00927251
NCT00927251
Completed
Not Applicable

Model 4296 Left Ventricular Lead Study

Medtronic Cardiac Rhythm and Heart Failure0 sites90 target enrollmentJune 2009
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Enrollment
90
Primary Endpoint
Number of Participants With Left Ventricular (LV)Lead Related Complications
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study is designed to show that a new lead, which paces the left bottom chamber (left ventricle) of the heart, is safe. Using a lead on the left side of the heart has been shown to potentially improve heart failure symptoms. The shape and size of this new lead may make it a good choice for patients or physicians.

Detailed Description

This study is a prospective, multi-center, non-randomized design trial. All consented patients who meet all inclusion and no exclusion criteria may receive the investigational lead. The study design has statistical power to show safety at one-month after implant.

Registry
clinicaltrials.gov
Start Date
June 2009
End Date
February 2010
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Cardiac Resynchronization Therapy (CRT)/Cardiac Resynchronization Therapy-Defibrillator (CRT-D) indications according to the European Society of Cardiology/American College of Cardiology/American Heart Association (ESC/ACC/AHA) guidelines
  • On optimal medical treatment according to investigator opinion
  • Indicated for implantable cardioverter defibrillator (ICD) if CRT-D is implanted
  • Patient consent
  • Geographically stable

Exclusion Criteria

  • Left Ventricular (LV) lead implant attempt in last 30 days
  • Unstable angina or acute myocardial infarction (MI) in past 30 days
  • Coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) in past 90 days
  • Contraindicated for transvenous pacing
  • Heart transplant
  • Contraindicated for less than 1 milligram (mg) dexamethasone acetate
  • Enrolled or intends to participate in concurrent drug and/or device study which would confound results
  • Life expectancy shorter than duration of the study
  • Exclusion criteria required by local law
  • Unable to tolerate urgent thoracotomy

Outcomes

Primary Outcomes

Number of Participants With Left Ventricular (LV)Lead Related Complications

Time Frame: Implant to one-month post implant

A LV lead related complication occurs when an invasive procedure is needed to correct an adverse event related to the LV lead.

Similar Trials